Core Insights - Gilead Sciences, Inc. reported better-than-expected fourth-quarter results with adjusted EPS of 1.90,surpassingtheZacksConsensusEstimateof1.67 and showing an increase from 1.72inthesamequarterlastyear[1][2]−Totalrevenuesreached7.6 billion, exceeding the Zacks Consensus Estimate of 7.1billionandreflectinga628.2 billion and 28.6billionandadjustedEPSintherangeof7.70-8.10[15]FinancialPerformance−Totalproductsalesrose77.5 billion, with HIV product sales growing 16% to 5.5billion,drivenbyincreaseddemandandfavorablepricing[4][5]−Biktarvy,theflagshipHIVtherapy,sawsalesincreaseby213.8 billion, capturing over 50% of the U.S. treatment market [5] - Descovy sales also increased by 21% year-over-year to 616million,maintainingover401.6 billion from 1.5 billion due to increased investments and clinical activities [12] - SG&A expenses increased by 16% to 1.9 billion, driven by litigation accrual and higher sales and marketing spending [13] 2024 Results - Revenues for 2024 increased by 6% to 28.8billion,surpassingtheZacksConsensusEstimateof28.2 billion [14] - EPS for 2024 was reported at 4.62,down316.72 in 2023 due to higher acquired IPR&D expenses and increased income tax expenses [14] 2025 Guidance - Gilead expects total product sales, excluding Veklury, to be between 26.8billionand27.2 billion, with total Veklury sales estimated at 1.4billion[15]−TheZacksConsensusEstimatefortotalproductsalesispeggedat28.3 billion [15] Pipeline Updates - The FDA granted Breakthrough Therapy Designation to Trodelvy for treating extensive-stage small cell lung cancer [16] - Gilead submitted applications for lenacapavir for HIV prevention, which could enhance its HIV franchise [17] Dividend Announcement - Gilead announced a 2.6% increase in its quarterly cash dividend, resulting in a quarterly dividend of $0.79 per share starting in the first quarter of 2025 [18] Market Performance - Gilead's shares surged 34.8% over the past year, contrasting with an 11.7% decline in the industry [3]
Gilead(GILD) ZACKS·2025-02-12 14:31